1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

Mobidiag Looks Inward To Solve COVID-19 Test Manufacturing Challenges

 
• By Catherine Longworth

With diagnostic companies facing supply chain issues and reagent shortages for COVID-19 tests, Finnish diagnostics company Mobidiag decided to take matters into its own hands. CEO Tuomas Tenkanen tells Medtech Insight how the company secured manufacturing capabilities in-house.

Coronavirus

Finnish diagnostics firm Mobidiag Ltd. will launch COVID-19 tests across Europe, following receipt of EU approval for its Novodiag and Amplidiag molecular assays to detect the SARS-CoV-2 virus. The tests were made available earlier this year in Finland, Sweden and France under emergency authorization approvals.

The Amplidiag COVID-19 assay, based on high-throughput PCR technology, is for use in large hospital labs, while Novodiag is a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

 
• By Elizabeth Orr

The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 
• By Brian Bossetta

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.

Exact Sciences’ Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

PathAI Talks PCCPs: ‘Accelerated Software Updates, Saves Time And Money’

 
• By Natasha Barrow

The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.

More from Device Area

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

Zimmer Biomet Targets 2027 Launch For Semi-Autonomous Orthopedic Robot After Monogram Acquisition

 
• By Shubham Singh

Zimmer Biomet expects the Monogram deal to meet its financial and strategic criteria, be neutral to adjusted earnings per share from 2025 through 2027 and become accretive thereafter.

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.